|
Friday, March 31, 2023 |
|
Sino Biopharm (1177.HK) Announces 2022 Annual Results |
Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022. more info >> |
|
Tuesday, August 23, 2022 |
|
中国生物制药(1177.HK)公布2022年中期业绩,收入上升5.9%至人民币151.94亿元 |
中国领先的创新研发驱动型医药集团—中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2022年6月30日止六个月(「期内」)之未经审核财务业绩。 more info >> |
|
中國生物製藥(1177.HK)公布2022年中期業績,收入上升5.9%至人民幣151.94億元 |
中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公布截至2022年6月30日止六個月(「期內」)之未經審核財務業績。 more info >> |
|
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the "Period"). more info >> |
|
Thursday, July 22, 2021 |
|
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic. more info >> |
|
中国生物制药捐资捐物人民币1,000万元驰援河南抗灾防疫 |
中国领先的创新研发驱动型医药集团—中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)宣布捐资捐物人民币1,000万元驰援河南抗灾防疫。 more info >> |
|
中國生物製藥捐資捐物人民幣1,000萬元馳援河南抗災防疫 |
中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)宣佈捐資捐物人民幣1,000萬元馳援河南抗災防疫。 more info >> |
|
Monday, May 24, 2021 |
|
中国生物制药2021年首季归属于母公司持有者应占盈利飙升118.5%至人民币19.14亿元 |
中国领先的创新研发驱动型医药集团—中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2021年3月31日止三个月之未经审核财务业绩。 more info >> |
|
中國生物製藥2021年首季歸屬於母公司持有者應佔盈利飆升118.5%至人民幣19.14億元 |
中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公佈截至2021年3月31日止三個月之未經審核財務業績。 more info >> |
|
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021. more info >> |
|
|
|